Selegiline transdermal system in major depressive disorder: profile report.
Frampton
James E
JE
Wolters Kluwer Health/Adis, Auckland, New Zealand. demail@adis.co.nz
Plosker
Greg L
GL
D000279:Administration, Cutaneous; D019540:Area Under Curve; D003865:Major Depressive Disorder / Q000188:drug therapy*; D003967:Diarrhea / Q000139:chemically induced; D004334:Drug Administration Schedule; D006207:Half-Life; D006261:Headache / Q000139:chemically induced; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D012642:Selegiline / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007319:Sleep Initiation and Maintenance Disorders / Q000139:chemically induced; D016896:Treatment Outcome; D014987:Xerostomia / Q000139:chemically induced
D008996:Monoamine Oxidase Inhibitors; D012642:Selegiline